Clinical Trial Update: Tumor Infiltrating Lymphocytes Adjuvant Therapy of Melanoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating tumor-infiltrating lymphocytes as adjuvant therapy for melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Tumor Infiltrating Lymphocytes (TIL) Adjuvant Therapy (tumor-infiltrating lymphocytes)

Snippet

Sponsor: Nantes University Hospital | Conditions: Melanoma | Phase 3 | Status: COMPLETED